Similarly, the pooled HR for CSS provided in nine studies indicated that Ki-67 expression was associated with worse survival in BC patients (HR = 1.69, 95% CI 1.47–1.95; P < 0.0001), with heterogeneity (I2 = 23%, P = 0.24; S5 Fig and Table 1). Here, MKI67 is linked to breast cancer.